Morphosys Ag (MOR) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MorphoSys AG has announced a delisting agreement with Novartis, following the latter’s successful acquisition and intent to merge with MorphoSys. Novartis, now holding over 91% of MorphoSys shares, plans to offer the remaining shareholders €68.00 per share to consolidate ownership. The transaction processes, including the delisting from Frankfurt Stock Exchange and NASDAQ, are expected to be completed in the third quarter of 2024.
For further insights into MOR stock, check out TipRanks’ Stock Analysis page.